Results: Serum TOS was higher in the patients [median 9.54 IQR 25-75 = 7.05-13.30 µmol H2O2 Eq/L] than in the healthy subjects [6.64 5.45-9.53 µmol H2O2 Eq/L] P
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Background/aim: To evaluate total oxidant status TOS , total antioxidant capacity TAC , and paraoxonase 1 PON1 levels in children with noncystic fibrosis CF bronchiectasis BE , and to compare these levels with those of healthy controls.
📊
Key Findings & Data:Materials and methods: Enrolled in the study were 118 children with non-CF BE and 68 healthy controls.
💡
Conclusion & Impact:Results: Serum TOS was higher in the patients [median 9.54 IQR 25-75 = 7.05-13.30 µmol H2O2 Eq/L] than in the healthy subjects [6.64 5.45-9.53 µmol H2O2 Eq/L] P
Background/aim: To evaluate total oxidant status TOS , total antioxidant capacity TAC , and paraoxonase 1 PON1 levels in children with noncystic fibrosis CF bronchiectasis BE , and to compare these levels with those of healthy controls. The study parameters were also evaluated according to some demographic, anthropometric, and clinical characteristics, as well as lung functions. Materials and methods: Enrolled in the study were 118 children with non-CF BE and 68 healthy controls. Serum TOS, TAC, and PON1 levels were determined. Lung function tests were performed by spirometry. Results: Serum TOS was higher in the patients [median 9.54 IQR 25-75 = 7.05-13.30 µmol H2O2 Eq/L] than in the healthy subjects [6.64 5.45-9.53 µmol H2O2 Eq/L] P
GEDİK, A. H., ÇAKIR, E., TÜRKMEN, A. V., ÖZER, Ö. F., KAYGUSUZ, S. B. (2020). Total oxidant and antioxidant status and paraoxonase 1 levels ofchildren with noncystic fibrosis bronchiectasis. Turkish Journal of Medical Sciences, Cilt: 50 - Sayı: 1, 1–8. https://ajindex.com/articles/113225
Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society Guideline for non-CF bronchiectasis. Thorax 2010; 65: 1-58
Bergin DA, Hurley K, Mehta A, Cox S, Ryan D, O’Neill SJ, Reeves EP, McElvaney NG. Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis. J Inflamm Res 2013; 6: 1-11
MacNee W. Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol 2001; 429: 195-207
Tzortzaki EG, Dimakou K, Neofytou E, Tsikritsaki K, Samara K, Avgousti M, Amargianitakis V, Gousiou A, Menikou S, Siafakas NM. Oxidative DNA damage and somatic mutations: a link to the molecular pathogenesis of chronic inflammatory airway diseases. Chest 2012; 141: 1243-1250
Heunks LMA, Dekhuijzen PN. Respiratory muscle function and free radicals: from cell to COPD. Thorax 2000; 55: 704-716
Litvinov D, Mahini H, Garelnabi M. Antioxidant and anti-inflammatory role of paraoxonase 1: antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases. N Am J Med Sci 2012; 4: 523-532
Mackness M, Mackness B. Targeting paraoxonase-1 in atherosclerosis. Expert Opin Ther Targets 2013; 17: 829-837
Nadeem A, Chhabra SK, Masood A, Raj HG. Increased oxidative stress and altered levels of antioxidants in asthma. J Allergy Clin Immunol 2003; 111: 72-78
Soler N, García-Heredia A, Marsillach J, Mackness B, Mackness M, Joven J, Romero P, Camps J. Paraoxonase-1 is associated with corneal endothelial cell alterations in patients with chronic obstructive pulmonary disease. Invest Ophthalmol Vis Sci 2013; 54: 5852-5858
Back EI, Frindt C, Nohr D, Frank J, Ziebach R, Stern M, Ranke M, Biesalski HK. Antioxidant deficiency in cystic fibrosis: when is the right time to take action? Am J Clin Nutr 2004; 80: 374-384
Lezo A, Biasi F, Massarenti P, Calabrese R, Poli G, Santini B, Bignamini E. Oxidative stress in stable cystic fibrosis patients: do we need higher antioxidant plasma levels? J Cyst Fibros 2013; 12: 35-41
Fuschillo S, De Felice A, Balzano G. Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J 2008; 31: 396-406
Tarpey MM, Wink DA, Grisham MB. Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations. Am J Physiol, Reg Integr Comp Physiol 2004; 286: 431-444